Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL243227 | 0.82 | CASP1 (0.45) | CA12TGM2ALDH1A1MEN1KMT2A | |
| SCHEMBL6242825 | 0.82 | CASP1 (0.45) | CA12TGM2ALDH1A1MEN1KMT2A | |
| SCHEMBL29139680 | 0.81 | NPC1 (0.41) | MMP2ALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL4211263 | 0.81 | MMP2 (0.46) | MMP2CA12TGM2NPC1RAB9A | |
| SCHEMBL6429045 | 0.81 | MMP2 (0.42) | MMP2CA12TGM2ALDH1A1NPC1 | |
| SCHEMBL10713625 | 0.80 | MMP8 (0.50) | ALDH1A1NPC1RAB9AMITFMAPT | |
| SCHEMBL4350738 | 0.77 | RAB9A (0.49) | MMP2TGM2ALDH1A1NPC1RAB9A | |
| SCHEMBL19358784 | 0.74 | EPHX1 (0.53) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL11874518 | 0.73 | CA12 (0.48) | MMP2CA12TGM2ALDH1A1NPC1 | |
| SCHEMBL233005 | 0.73 | CA12 (0.48) | MMP2CA12ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101128199-B | Monocyclic heterocycles as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2013-07-24 | — | — | CN | disclosed |
| US-7989477-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1737451-B1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20100183606-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-22 | — | — | US | disclosed |
| US-7714138-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090054436-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-26 | — | — | US | disclosed |
| US-7459562-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| CN-101128199-A | Monocyclic heterocycles as kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2008-02-20 | — | — | CN | disclosed |
| EP-1737451-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005117867-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054436-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | CDK2, MAP3K19, CDK1 | MMP2 3399/4885CA12 4106/4885TGM2 2273/4885 |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | CDK2, MAP3K19, CDK1 | MMP2 3399/4885CA12 4106/4885TGM2 2273/4885 |
| US-20100183606-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | CDK2, MAP3K19, CDK1 | MMP2 3399/4885CA12 4106/4885TGM2 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.